CXR Biosciences will retain its name and operate under the Concept Life Sciences Group umbrella. All CXR staff will join the Concept Life Sciences’ Group, and CXR Biosciences CEO Paul Smith will continue to head up the business. CXR will continue to provide its customers with its investigative toxicology, exploratory toxicology and metabolism and pharmacokinetics services from its laboratory base in Dundee, U.K.
Led by Executive Chairman Michael Fort and Chief Executive Officer Alan Morgan, the Concept Life Sciences Group currently has more than 600 staff members in 11 core locations, with advanced plans for further expansion into continental Europe. The deals marks its fourth acquisition since it was formed in July 2014.
CXR Biosciences is an investigative and exploratory toxicology business. Its in-house expertise assists leading agrochemical, chemical, pharmaceutical, biotechnology and consumer products companies in resolving issues relating to the safety of compounds, and with the selection of drug and chemical candidates.